Dalbavancin as sequential therapy for infective endocarditis due to Gram-positive organisms: a review

Fazili, Tasaduq; Bansal, Ekta; Garner, Dorothy C; Gómez, Mariana; Stornelli, Nicholas

doi:10.1016/j.ijantimicag.2023.106749

Cited by 23 publications

(9 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Here we described the key evidence in off-label indications in clinical practice. [4]. Overall, in this report, 49% were native valve IE, 47% prosthetic valve IE and 12% cardiac device-related infection.…”

Section: N Off-label Indicationsmentioning

confidence: 52%

“…It is only available as an intravenous formulation [1]. The main difference from older glycopeptides is the addition of lipophilic side chains, which allows binding to the D-alanyl-D-alanine portion of the peptidoglycan subunit, preventing transglycosylation and cross-linking of peptide bridges within bacterial peptidoglycan cell walls [2], with greater affinity than the older glycopeptides [3,4]. This activity is limited to Gram-positive microorganisms, as the porin channels of the outer cell membrane in Gram-negative bacteria prevent lipoglycopeptides from reaching their target [4].…”

Section: Dalbavancinmentioning

confidence: 99%

See 1 more Smart Citation

The role of long-acting antibiotics in the clinical practice: a narrative review

2023

Infez Med

View full text Add to dashboard Cite

L ong-acting antibiotics, such as dalbavancin and oritavancin, have emerged as important tools in the fight against bacterial infections. Ini-tially approved for treating acute bacterial skin and skin structure infections (ABSSSI), they have gained attention for potential off-label use due to their extended half-lives, their excellent tissue penetration, which allows prolonged high therapeutic concentrations at the site of infection in many difficult to treat sites as bone, their in vitro demonstrated efficacy against biofilm, their potent activity against a broad spectrum of Gram-positive bacteria, along with a favourable safety pro-

show abstract

Section: N Off-label Indicationsmentioning

confidence: 52%

Section: Dalbavancinmentioning

confidence: 99%

The role of long-acting antibiotics in the clinical practice: a narrative review

2023

Infez Med

View full text Add to dashboard Cite

show abstract

“…In the USA and Europe, acute bacterial skin and skin structure infections (ABSSSIs) are the only conditions for which dalbavancin is currently licensed [ 117 ].…”

Section: Glycopeptidesmentioning

confidence: 99%

Synthetic and Semisynthetic Compounds as Antibacterials Targeting Virulence Traits in Resistant Strains: A Narrative Updated Review

et al. 2023

View full text Add to dashboard Cite

This narrative review paper provides an up-to-date overview of the potential of novel synthetic and semisynthetic compounds as antibacterials that target virulence traits in resistant strains. The review focused on research conducted in the last five years and investigated a range of compounds including azoles, indoles, thiophenes, glycopeptides, pleuromutilin derivatives, lactone derivatives, and chalcones. The emergence and spread of antibiotic-resistant bacterial strains is a growing public health concern, and new approaches are urgently needed to combat this threat. One promising approach is to target virulence factors, which are essential for bacterial survival and pathogenesis, but not for bacterial growth. By targeting virulence factors, it may be possible to reduce the severity of bacterial infections without promoting the development of resistance. We discuss the mechanisms of action of the various compounds investigated and their potential as antibacterials. The review highlights the potential of targeting virulence factors as a promising strategy to combat antibiotic resistance and suggests that further research is needed to identify new compounds and optimize their efficacy. The findings of this review suggest that novel synthetic and semisynthetic compounds that target virulence factors have great potential as antibacterials in the fight against antibiotic resistance.

show abstract

“…Moreover, dalbavancin has been shown to have important activities in in vitro models of experimental endocarditis due to Staphylococcus aureus with or without reduced susceptibility to vancomycin and teicoplanin [8]. This evidence provided the rationale for clinical studies that documented the efficacy and cost-effectiveness of dalbavancin for the sequential treatment of patients with infective endocarditis [9][10][11].…”

Section: Introductionmentioning

confidence: 99%

Therapeutic Drug Monitoring of Dalbavancin in Real Life: A Two-Year Experience

Cattaneo,

Fusi,

Colaneri

et al. 2023

Antibiotics

View full text Add to dashboard Cite

Dalbavancin is a long-acting lipoglycopeptide that is registered for the treatment of acute bacterial skin and skin structure infections, and it is also increasingly used for infections that require prolonged antibiotic treatment. Here, we present the results from the first 2 years of a service set up in December 2021 for the therapeutic drug monitoring (TDM) of dalbavancin in clinical settings. In particular, we compared the trough concentration (Cmin) to maximum concentration (Cmax) in patients with osteoarticular infections receiving prolonged treatment with dalbavancin. Log-linear regression models were used to estimate the timing of dalbavancin administration with the goal of maintaining Cmin concentrations of >8 mg/L in the two TDM-based strategies. From December 2021 to November 2023, 366 TDMs of dalbavancin from 81 patients were performed. The Cmin and Cmax concentrations of dalbavancin ranged from 4.1 to 70.5 mg/L and from 74.9 to 995.6 mg/L, respectively. With log-linear regression models, we estimated that each injection should be administered every 42–48 days to maintain the Cmin concentrations. Out of the 81 patients, 37 received at least three doses of dalbavancin for the treatment of osteoarticular infections. Despite there being no significant differences in the days of dalbavancin treatment (130 ± 97 versus 106 ± 102 days), the patients in the Cmax-based TDM group received a significantly lower number of dalbavancin injections (5.2 ± 1.8 versus 7.3 ± 2.6 injections, p = 0.005), and they were administered over a longer period of time (40 ± 10 versus 29 ± 14 days, p = 0.013) than in the Cmin-based TDM group. In conclusion, Cmax-based TDM was associated with a significant reduction in the inter-individual variability of dalbavancin concentrations and lower drug dosing frequency than those of Cmin-based TDM. This approach could, therefore, favor a more rational and targeted use of dalbavancin in patients requiring prolonged treatment.

show abstract

Dalbavancin as sequential therapy for infective endocarditis due to Gram-positive organisms: a review

Cited by 23 publications

References 27 publications

The role of long-acting antibiotics in the clinical practice: a narrative review

The role of long-acting antibiotics in the clinical practice: a narrative review

Synthetic and Semisynthetic Compounds as Antibacterials Targeting Virulence Traits in Resistant Strains: A Narrative Updated Review

Therapeutic Drug Monitoring of Dalbavancin in Real Life: A Two-Year Experience

Contact Info

Product

Resources

About